




The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 140% points. The greatest weakness of Enanta Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 489%, being 226% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	170,641
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,704
Liabilities, Non-Current	1,713
Other Assets	69,486
Other Compr. Net Income	133
Other Expenses	46,463
Other Liabilities	1,439
Other Net Income	1,307
Other Revenues	160,880
Property and Equipment	5,886
Research and Development	23,189
Selling, General and Administrative Expense	13,543

Output Variable	Value in 1000 USD
Assets	246,013
Liabilities	9,856
Expenses	83,195
Revenues	160,880
Stockholders Equity	236,157
Net Income	78,992
Comprehensive Net Income	79,058
BaseVar	250,692
ECR before Limited Liability	464%
Economic Capital Ratio	489%